Cargando…
Mechanism of TangGanJian on nonalcoholic fatty liver disease with type 2 diabetes mellitus
Context: TangGanJian (TGJ) has a curative effect in the clinical treatment of nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes mellitus (T2DM), while the mechanism involved in the treatment process remains unclear. Objective: This study details the mechanism of TGJ on the treatment of N...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6249541/ https://www.ncbi.nlm.nih.gov/pubmed/30460863 http://dx.doi.org/10.1080/13880209.2018.1504972 |
_version_ | 1783372774116425728 |
---|---|
author | Fan, Yanbo Xiong, Wei Li, Jingjing Hu, Aimin He, Zhiwei Zhang, Jiawen Zhou, Guoyun Yin, Qiang |
author_facet | Fan, Yanbo Xiong, Wei Li, Jingjing Hu, Aimin He, Zhiwei Zhang, Jiawen Zhou, Guoyun Yin, Qiang |
author_sort | Fan, Yanbo |
collection | PubMed |
description | Context: TangGanJian (TGJ) has a curative effect in the clinical treatment of nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes mellitus (T2DM), while the mechanism involved in the treatment process remains unclear. Objective: This study details the mechanism of TGJ on the treatment of NAFLD with T2DM. Materials and methods: NAFLD was induced in T2DM rat model. Male Wistar rats were assigned into six groups: Group I (control), Group II (model), Group III (pioglitazone, 0.5 mg/kg), Group IV (high dose of TGJ, 24.8 g/kg), Group V (middle dose of TGJ, 12.4 g/kg) and Group VI (low dose of TGJ, 6.2 g/kg). All rats in each group were treated with the corresponding drugs by gavage for 8 weeks. Haematoxylin and eosin analysis was conducted. The indicators of inflammatory and oxidative stress were analysed utilizing one-way ANOVA. Results: The contents of TNF-α (15.794 ± 3.302 pg/mL), IL-6 (76.801 ± 8.491 pg/mL), IL-1β (100.101 ± 13.150 pg/mL), CRP (1.052 ± 0.079 pg/mL) and MDA (3.972 ± 0.159 pg/mL) were obviously elevated in NAFLD with T2DM rats compared to controls. Except for the IL-6, the levels of other markers declined in a dose-dependent manner after treatment with TGJ. The SOD (14.139 ± 1.479 U/mgprot) and GSH-PX (81.511 ± 5.276 U/mgprot) levels significantly decreased in NAFLD with T2DM rats, while the levels of these indicators increased after treatment with TGJ. Conclusions: TGJ may be a therapy for the NAFLD with T2DM rats by modulating the inflammatory response and the oxidative stress capacity. |
format | Online Article Text |
id | pubmed-6249541 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-62495412018-11-26 Mechanism of TangGanJian on nonalcoholic fatty liver disease with type 2 diabetes mellitus Fan, Yanbo Xiong, Wei Li, Jingjing Hu, Aimin He, Zhiwei Zhang, Jiawen Zhou, Guoyun Yin, Qiang Pharm Biol Research Article Context: TangGanJian (TGJ) has a curative effect in the clinical treatment of nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes mellitus (T2DM), while the mechanism involved in the treatment process remains unclear. Objective: This study details the mechanism of TGJ on the treatment of NAFLD with T2DM. Materials and methods: NAFLD was induced in T2DM rat model. Male Wistar rats were assigned into six groups: Group I (control), Group II (model), Group III (pioglitazone, 0.5 mg/kg), Group IV (high dose of TGJ, 24.8 g/kg), Group V (middle dose of TGJ, 12.4 g/kg) and Group VI (low dose of TGJ, 6.2 g/kg). All rats in each group were treated with the corresponding drugs by gavage for 8 weeks. Haematoxylin and eosin analysis was conducted. The indicators of inflammatory and oxidative stress were analysed utilizing one-way ANOVA. Results: The contents of TNF-α (15.794 ± 3.302 pg/mL), IL-6 (76.801 ± 8.491 pg/mL), IL-1β (100.101 ± 13.150 pg/mL), CRP (1.052 ± 0.079 pg/mL) and MDA (3.972 ± 0.159 pg/mL) were obviously elevated in NAFLD with T2DM rats compared to controls. Except for the IL-6, the levels of other markers declined in a dose-dependent manner after treatment with TGJ. The SOD (14.139 ± 1.479 U/mgprot) and GSH-PX (81.511 ± 5.276 U/mgprot) levels significantly decreased in NAFLD with T2DM rats, while the levels of these indicators increased after treatment with TGJ. Conclusions: TGJ may be a therapy for the NAFLD with T2DM rats by modulating the inflammatory response and the oxidative stress capacity. Taylor & Francis 2018-11-21 /pmc/articles/PMC6249541/ /pubmed/30460863 http://dx.doi.org/10.1080/13880209.2018.1504972 Text en © 2018 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Fan, Yanbo Xiong, Wei Li, Jingjing Hu, Aimin He, Zhiwei Zhang, Jiawen Zhou, Guoyun Yin, Qiang Mechanism of TangGanJian on nonalcoholic fatty liver disease with type 2 diabetes mellitus |
title | Mechanism of TangGanJian on nonalcoholic fatty liver disease with type 2 diabetes mellitus |
title_full | Mechanism of TangGanJian on nonalcoholic fatty liver disease with type 2 diabetes mellitus |
title_fullStr | Mechanism of TangGanJian on nonalcoholic fatty liver disease with type 2 diabetes mellitus |
title_full_unstemmed | Mechanism of TangGanJian on nonalcoholic fatty liver disease with type 2 diabetes mellitus |
title_short | Mechanism of TangGanJian on nonalcoholic fatty liver disease with type 2 diabetes mellitus |
title_sort | mechanism of tangganjian on nonalcoholic fatty liver disease with type 2 diabetes mellitus |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6249541/ https://www.ncbi.nlm.nih.gov/pubmed/30460863 http://dx.doi.org/10.1080/13880209.2018.1504972 |
work_keys_str_mv | AT fanyanbo mechanismoftangganjianonnonalcoholicfattyliverdiseasewithtype2diabetesmellitus AT xiongwei mechanismoftangganjianonnonalcoholicfattyliverdiseasewithtype2diabetesmellitus AT lijingjing mechanismoftangganjianonnonalcoholicfattyliverdiseasewithtype2diabetesmellitus AT huaimin mechanismoftangganjianonnonalcoholicfattyliverdiseasewithtype2diabetesmellitus AT hezhiwei mechanismoftangganjianonnonalcoholicfattyliverdiseasewithtype2diabetesmellitus AT zhangjiawen mechanismoftangganjianonnonalcoholicfattyliverdiseasewithtype2diabetesmellitus AT zhouguoyun mechanismoftangganjianonnonalcoholicfattyliverdiseasewithtype2diabetesmellitus AT yinqiang mechanismoftangganjianonnonalcoholicfattyliverdiseasewithtype2diabetesmellitus |